NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $4.51 +0.18 (+4.16%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.35▼$4.7550-Day Range$3.08▼$4.4552-Week Range$2.28▼$8.51Volume1.36 million shsAverage Volume1.55 million shsMarket Capitalization$664.64 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Adaptive Biotechnologies alerts: Email Address Adaptive Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside50.8% Upside$6.80 Price TargetShort InterestBearish8.08% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.13 out of 5 starsMedical Sector206th out of 936 stocksBiological Products, Except Diagnostic Industry26th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptive Biotechnologies has received no research coverage in the past 90 days.Read more about Adaptive Biotechnologies' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.08% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Adaptive Biotechnologies has recently decreased by 1.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 3.7 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.Search Interest8 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.29) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Adaptive Biotechnologies Stock (NASDAQ:ADPT)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Read More ADPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Stock News HeadlinesJuly 26 at 6:58 PM | theglobeandmail.comClosing Bell: GX Resolve Adaptive Asset Allctn Corp Cls ETF down on Thursday (HRAA)July 26 at 6:58 PM | finance.yahoo.comFidus Awarded AMD Adaptive Compute Partner of the YearJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 3:38 AM | americanbankingnews.comAdaptive Biotechnologies (ADPT) Set to Announce Earnings on ThursdayJuly 21, 2024 | investorplace.com3 Precision Medicine Stocks Tailoring TreatmentsJuly 17, 2024 | americanbankingnews.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Large Drop in Short InterestJuly 11, 2024 | globenewswire.comAdaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024May 31, 2024 | globenewswire.comAdaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid CongressJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | globenewswire.comAdaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 25, 2024 | finance.yahoo.comARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?May 24, 2024 | insidermonkey.comDoes Adaptive Biotechnologies Corporation (ADPT) Have Strong Growth Potential?May 23, 2024 | bizjournals.comAdaptive Sports Northwest's Jen Armbruster on making businesses more inclusive to those with disabilitiesMay 23, 2024 | investorplace.comMighty Mites: 3 Small-Cap Stocks Packing a Powerful PunchMay 22, 2024 | venturebeat.comSkymel’s NeuroSplit™ Adaptive Inferencing Lets AI Companies Run the Latest GenAI Models – Even on Older GPUsMay 22, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMay 15, 2024 | finance.yahoo.comAdaptive Biotechnologies Corporation (ADPT)May 9, 2024 | finance.yahoo.comAdaptive Biotechnologies First Quarter 2024 Earnings: Beats ExpectationsSee More Headlines Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees709Year Founded2009Price Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+50.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-225,250,000.00 Net Margins-123.24% Pretax Margin-123.29% Return on Equity-56.58% Return on Assets-27.45% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.35 Sales & Book Value Annual Sales$170.28 million Price / Sales3.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book2.12Miscellaneous Outstanding Shares147,370,000Free Float138,231,000Market Cap$664.64 million OptionableOptionable Beta1.35 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Julie Rubinstein (Age 52)President & COO Comp: $721.04kDr. Harlan S. Robins Ph.D. (Age 51)Co-Founder & Chief Scientific Officer Comp: $711.09kMs. Stacy L. Taylor (Age 64)Senior VP, General Counsel & Corporate Secretary Ms. Mary Pat LancelottaSenior Vice President of MRD BioPharmaKey CompetitorsFluidigmNASDAQ:FLDMKodiak SciencesNASDAQ:KODCG OncologyNASDAQ:CGONIovance BiotherapeuticsNASDAQ:IOVABeam TherapeuticsNASDAQ:BEAMView All CompetitorsInsiders & InstitutionsARK Investment Management LLCBought 850,704 shares on 7/26/2024Ownership: 7.744%Bank of New York Mellon CorpBought 64,788 shares on 7/26/2024Ownership: 0.312%Legato Capital Management LLCBought 81,648 shares on 7/26/2024Ownership: 0.142%Nisa Investment Advisors LLCBought 11,852 shares on 7/20/2024Ownership: 0.009%Sumitomo Mitsui Trust Holdings Inc.Bought 722,924 shares on 7/19/2024Ownership: 4.682%View All Insider TransactionsView All Institutional Transactions ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $4.90 on January 1st, 2024. Since then, ADPT stock has decreased by 8.0% and is now trading at $4.51. View the best growth stocks for 2024 here. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. The company's revenue was up 11.2% compared to the same quarter last year. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Top institutional investors of Adaptive Biotechnologies include ARK Investment Management LLC (7.74%), Sumitomo Mitsui Trust Holdings Inc. (4.68%), Bank of New York Mellon Corp (0.31%) and Legato Capital Management LLC (0.14%). Insiders that own company stock include Chad M Robins, Tycho Peterson, Julie Rubinstein, Nitin Sood, R Mark Adams, Stacy L Taylor, Kyle Piskel, Michelle Renee Griffin, Lance Baldo, Harlan S Robins and Chad M Cohen. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Home Depot (HD). This page (NASDAQ:ADPT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
